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Background: Inﬂuenza vaccine composition is reevaluated each year due to the frequency and accumulation of
genetic changes that inﬂuenza viruses undergo. The beginning of the 2016–2017 inﬂuenza surveillance period in
Israel has been marked by the dominance of inﬂuenza A(H3N2).
Objectives: To evaluate the type, subtype, genetic evolution and amino acid substitutions of inﬂuenza A(H3N2)
viruses detected among community patients with inﬂuenza-like illness (ILI) and hospitalized patients with re-
spiratory illness in the ﬁrst weeks of the 2016–2017 inﬂuenza season.
Study design: Respiratory samples from community patients with inﬂuenza-like illness and from hospitalized
patients underwent identiﬁcation, subtyping and molecular characterization. Hemagglutinin sequences were
compared to the vaccine strain, phylogenetic tree was created, and amino acid substitutions were determined.
Results: Inﬂuenza A(H3N2) predominated during the early stages of the 2016–2017 inﬂuenza season.
Noticeably, approximately 20% of community patients and 36% of hospitalized patients, positive for inﬂuenza3),
received the 2016–2017 inﬂuenza vaccine. The inﬂuenza A(H3N2) viruses demonstrated genetic divergence
from the vaccine strain into three separate subgroups within the 3C.2a clade. One resembled the new 3C.2a1
subclade, one resembled the recently proposed 3C.2a2 subclade and the other was not previously described.
Diversity was observed within each subgroup, in terms of additional amino acid substitutions.
Conclusions: Characterization of the 2016–2017 A(H3N2) inﬂuenza viruses is imperative for determining the
future inﬂuenza vaccine composition.
1. Background
Inﬂuenza vaccine composition is evaluated each year due to the
frequency and accumulation of genetic changes that inﬂuenza viruses
undergo. The beginning of the 2016–2017 inﬂuenza surveillance period
in Israel has been marked by the dominance of inﬂuenza A(H3N2) virus
infection both among community and hospitalized patients. Inﬂuenza
A(H3N2) is considered the most common cause of seasonal inﬂuenza
[1], and has been associated with most inﬂuenza-related deaths [2].
Hemagglutinin (HA) amino acid (AA) substitutions are considered
to occur more frequently for inﬂuenza A(H3N2) than inﬂuenza
A(H1N1) viruses [3], and vaccine eﬀectiveness (VE) against inﬂuenza
A(H3N2) has been overall lower than VE against inﬂuenza A(H1N1) or
against inﬂuenza B [4]. Thus, it is of paramount importance to detect
AA substitutions in the circulating inﬂuenza A(H3N2) viruses relative to
the recommended vaccine strain as early in the inﬂuenza season as
possible. In this work, we analyzed inﬂuenza A(H3N2) viruses detected
early in the season in respiratory samples of inﬂuenza patients that
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were either vaccinated or not vaccinated with the 2016–2017 inﬂuenza
vaccine.
2. Study design
2.1. Sample collection
Respiratory samples were collected from patients hospitalized with
respiratory illness at the Chaim Sheba Medical Center, Israel, and from
patients with inﬂuenza-like illness (ILI) from 26 outpatient sentinel
clinics throughout Israel. The latter were collected as a part of the Israel
Center for Disease Control (ICDC) surveillance program for respiratory
viruses morbidity.
Sheba Medical Center institutional review board (IRB) approval was
obtained (Helsinki Number 1967-15-SMC).
2.2. Laboratory techniques
Viral genomic RNA was extracted from respiratory samples using
the NucliSENS easyMAG (BioMerieux, France). Inﬂuenza A, Inﬂuenza B
and A(H1N1)pdm09 infection was detected by using a panel of real-
time reverse transcription-PCR (rRT-PCR), as previously described
[5,6]. For inﬂuenza A(H3N2) detection and sequencing speciﬁc primers
were used as previously described [7].
RT-PCR products were sequenced using ABI PRISM Dye Deoxy
Terminator cycle sequencing kit (Life Technology, Foster City, CA,
USA). Reaction mixtures were analyzed on Applied Biosystems 3500
sequence analyzer.
Nucleic acid sequences were aligned and compared using the
Sequencher® 5.0 program (Gencodes Corporation, Ann Arbor, MI). To
infer the evolutionary relationships and the most recent common an-
cestor (MRCA) for the inﬂuenza A(H3N2) virus HA sequences, a
Bayesian Markov chain Monte Carlo (MCMC) method was applied using
a relaxed molecular clock, as implemented in the BEAST program
(version 1.7.5). Trees were visualized and edited with the FigTree
program (version 1.4.2) [8]. Selected HA sequences were deposited in
GenBank under the following accession number designation:
KY435815.1, KY435816.1, KY435817.1, KY435818.1, KY435819.1,
KY435820.1, KY435821.1, KY435822.1, KY435823.1, KY435824.1,
KY435825.1, KY435826.1 (Table 1).
2.3. Cell culture and hemagglutination inhibition analysis
Inﬂuenza viruses were grown in Madin-Darby canine kidney
(MDCK) cells stable transfected with the cDNA of human 2,6-sial-
transferase (SIAT1) as previously described [9].
Hemmagglutination assays were performed using ﬁfty microliters of
0.75% guinea pig red blood cells in the presence of 20 nM oseltamivir
Table 1
Inﬂuenza A(H3N2) virus hemagglutinin sequences used in phylogenetic analysis.
Virus isolate Sequence source Accession Number Country Originating laboratory
A/Texas/50/2012 GISAID EpiFlu EPI377499 United States Texas Department of State Health Services-Laboratory, Austin, United States
A/Nevada/34/2015 GISAID EpiFlu EPI633977 United States Southern Nevada Public Health Lab United States
A/Bolzano/7/2016 GISAID EpiFlu EPI773595 Italy Istituto Superiore di Sanità Roma,Italy
A/Hawaii/54/2016 GISAID EpiFlu EPI814213 United States State of Hawaii Department of Health Medical Microbiology Branch, United States
A/Wisconsin/85/2016 GISAID EpiFlu EPI857055 United States Wisconsin State Laboratory of Hygiene, Virology Unit, United States
A/Illinois/07/2016 GISAID EpiFlu EPI752842 United States Illinois Department of Public Health-Chicago, United States
A/Hong Kong/4801/2014 GISAID EpiFlu EPI539574 China Government Virus Unit, Hong Kong (SAR)
A/Nebraska/04/2014 GISAID EpiFlu EPI520356 United States Nebraska Public Health Lab, United States
A/Switzerland/9715293/2013 GISAID EpiFlu EPI530687 Switzerland Hopital Cantonal Universitaire de Geneves, Switzerland
A/Samara/73/2013 GISAID EpiFlu EPI460558 Russian Federation WHO National Inﬂuenza Centre, Russian Federation
A/New Castele/22/2014 GISAID EpiFlu EPI543132 Australia WHO Collaborating Centre for Reference and Research on Inﬂuenza, Melbourne,
Australia
A/Victoria/361/2011 GISAID EpiFlu EPI349103 Australia A Melbourne Pathology, Victoria Pde, Australia
A/Perth/16/2009 GISAID EpiFlu EP1210071 Australia WHO Collaborating Centre for Reference and Research on Inﬂuenza, Melbourne,
Australia
A/Wyoming/3/2003 GISAID EpiFlu EPI385944 United States Not available
A/Israel/P451/2015 GISAID EpiFlu EPI620485 Israel Central Virology Laboratory (NIC) Israel
A/Israel/P291/2014 GISAID EpiFlu EPI563104 Israel Central Virology Laboratory (NIC) Israel
A/Israel/P659/2015 GISAID EpiFlu EPI620486 Israel Central Virology Laboratory (NIC) Israel
A/Israel/P151/2014 GISAID EpiFlu EPI620489 Israel Central Virology Laboratory (NIC) Israel
A/Israel/P687/2015 GISAID EpiFlu EPI620488 Israel Central Virology Laboratory (NIC) Israel
A/Israel/17/2013 GISAID EpiFlu EPI426073 Israel Central Virology Laboratory (NIC) Israel
A/Israel/Z1225/2014 GISAID EpiFlu EPI539814 Israel Central Virology Laboratory (NIC) Israel
A/Israel/32/2013 GISAID EpiFlu EPI505186 Israel Central Virology Laboratory (NIC) Israel
A/Israel/Z774/2014 GISAID EpiFlu EPI516911 Israel Central Virology Laboratory (NIC) Israel
A/Israel/19/2013 GISAID EpiFlu EPI426075 Israel Central Virology Laboratory (NIC) Israel
A/Israel/Z125/2013 GISAID EpiFlu EPI515191 Israel Central Virology Laboratory (NIC) Israel
A/Israel/35/2011 GISAID EpiFlu EPI354187 Israel Central Virology Laboratory (NIC) Israel
A/Israel/18/2011 GISAID EpiFlu EPI319254 Israel Central Virology Laboratory (NIC) Israel
A/Israel/20/2013 GISAID EpiFlu EPI426077 Israel Central Virology Laboratory (NIC) Israel
A/Israel/4/2011 GISAID EpiFlu EPI319256 Israel Central Virology Laboratory (NIC) Israel
A/Israel/R83/2016 GenBank KY435815 Israel Central Virology Laboratory (NIC) Israel
A/Israel/R147/2016 GenBank KY435816 Israel Central Virology Laboratory (NIC) Israel
A/Israel/R199/2016 GenBank KY435817 Israel Central Virology Laboratory (NIC) Israel
A/Israel/R245/2016 GenBank KY435818 Israel Central Virology Laboratory (NIC) Israel
A/Israel/R246/2016 GenBank KY435819 Israel Central Virology Laboratory (NIC) Israel
A/Israel/R248/2016 GenBank KY435820 Israel Central Virology Laboratory (NIC) Israel
A/Israel/R250/2016 GenBank KY435821 Israel Central Virology Laboratory (NIC) Israel
A/Israel/R255/2016 GenBank KY435822 Israel Central Virology Laboratory (NIC) Israel
A/Israel/R256/2016 GenBank KY435823 Israel Central Virology Laboratory (NIC) Israel
A/Israel/R274/2016 GenBank KY435824 Israel Central Virology Laboratory (NIC) Israel
A/Israel/B5990/2016 GenBank KY435825 Israel Central Virology Laboratory (NIC) Israel
A/Israel/B6014/2016 GenBank KY435826 Israel Central Virology Laboratory (NIC) Israel
A/Israel/B6105/2016 GenBank KY435827 Israel Central Virology Laboratory (NIC) Israel
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carboxylate suspended in PBS. For Hemagglutination inhibition ana-
lysis (HAI), two-fold serial dilutions of 25 μl antiserum raised against
the egg-propagated A/Hong Kong/4801/2014 vaccine virus were pre-
pared in V-shaped 96 well microtiter plates, and an equal volume of
four HA units (determined in the Hemmagglutination assays), were
added. The assay was performed with guinea pig red blood cells in the
presence of 20 nM oseltamivir. The mixture was mixed by shaking the
plates on a mechanical vibrator and then incubated at room tempera-
ture for 1 h. Agglutination patterns were read after 60 min and the
hemagglutination inhibition (HI) titer was deﬁned as the reciprocal of
the last dilution of serum that fully inhibited hemagglutination [10].
3. Results
Of the 388 samples obtained from community sentinel patients with
ILI from October 2nd through December 9th, 2016, 59 (15.2%) were
positive for inﬂuenza viruses. Of these, 56 (94.9%) were positive for
inﬂuenza A(H3N2), one (1.7%) for inﬂuenza A(H1N1)pdm09 and two
(3.4%) for inﬂuenza B virus. A total of 11 (20%) individuals who were
infected with inﬂuenza A(H3N2) received the inﬂuenza vaccine 14 days
or more prior to developing ILI.
Out of the 1023 samples received from hospitalized patients, 55
(5.4%) were positive for inﬂuenza; of these, 53 (96.4%) were positive
for inﬂuenza A(H3N2), 1 (1.8%) for inﬂuenza A(H1N1)pdm09, and 1
(1.8%) for inﬂuenza B. Nineteen (36%) of the inﬂuenza A(H3N2)-hos-
pitalized patients received the inﬂuenza vaccine 21 days or more prior
to hospitalization, 13 were not vaccinated and for 21 patients vaccine
information was unavailable. All hospitalized patients had underlying
chronic diseases: 34% had cardiovascular diseases, 28% pulmonary
diseases, 19% malignancy, 15% hypertension, 6% diabetes, 4% neu-
rological diseases, 4% endocrine/metabolic diseases and 4% were
pregnant.
Sequence analysis of the HA gene of 18 inﬂuenza A(H3N2) viruses
(13 from outpatient sentinel clinic samples, and ﬁve hospital samples)
that were representative of the entire study period was carried out.
Table 2 demonstrates three main diﬀerent groups of AA substitutions as
compared with the vaccine A/Hong Kong/4801/2014 (H3N2) cell-
propagated virus. Group 1 had the AA substitutions N171K (HA1), I77V
(HA2) and G155E (HA2) which deﬁne the newly described clade
3C.2a1 [11]. Group 2 had the T131K (HA1) and R261Q (HA1) sub-
stitutions, with an additional substitution in codon position 142 (HA1),
consisting of either R142K or R142E. Group 3 had the N121K (HA1)
and S144K (HA1) substitutions (Table 2).
Ninety four percent (18 of 19) of the viruses had AA substitutions in
antigenic site A (Table 2). Speciﬁcally, N121K (HA1) occurred in 67%
(12 of 18) of the viruses, S144K (HA1) was observed in 56% (10 of 18),
and T131K (HA1) occurred in 22% (4 of 18) of the viruses. Thirty three
percent (6 of 18) of the viruses had AA substitutions in position 142
(HA1); 3 (16.7%) were R142K, 2 (11%) R142G and 1 (5.5%) was
R142E.
Two AA substitutions, N122D and N246Y, resulted in a loss of a
potential glycosylation site (Table 2).
Fig. 1 shows the protein structure of a representative virus from
each group of AA substitutions. Phylogenetic analysis of 18 partially
sequenced A(H3N2) HA genes (928 base pairs) using the BEAST pro-
gram showed branching of the inﬂuenza A(H3N2) HA sequences
(Fig. 2). One branch was related to the previously described 3C.2a1
subclade [11](marked with turquoise branches and designated as group
1) (Fig. 2). A second branch was related to the recently proposed
3C.2a2 subclade [12] (marked with green branches, designated as
group 3) (Fig. 2).
To determine if these new clades are associated with an antigenic
drift we performed HAI testing (as described in materials and methods),
however we were unable to obtain hemagglutination using Guinea pigs
red blood cells in the presence of oseltamivir carboxylate. Similarly,
90% of the viruses that were tested by the WHO did not hemagglutinate
[14]. Additional inﬂuenza viruses from Israel were analyzed for HAI by
the WHO Collaborating Centre for Reference and Research on Inﬂu-
enza. Of the six inﬂuenza viruses analyzed so far, four could not ag-
glutinate red blood cells at all, and thus could not be analyzed for HAI.
Table 2
Amino acid (AA) substitutions in the HA gene for inﬂuenza A(H3N2) viruses from Israel. Colored cells highlight AA substitutions that are common to all viruses that are part of a
certain AA substitution group. Dots represent AAs that match the vaccine A(H3N2) virus sequence. Sample numbers are highlighted in color according to inﬂuenza vaccination status:
vaccinated–yellow, non-vaccinated–pink, unknown–brown. AA glycosylation is marked in bold letters. (For interpretation of the references to color in this table legend, the reader is
referred to the web version of this article.)
Clade
AA Sub.
Group
HA subunits HA1 HA2
Codon position HA 27 31 33 78 92 93 106 121 122 131 142 144 168 171 173 214 219 245 246 261 262 311 77 150 155 176 .
Antigenic site A A A A A D D D B C
A/Hong 
Kong/4801/2014 3C.2a K N R G K A A N N T R S M N Q I S I N R S H I G G V
A/Israel/R36/2016 3C.2a1 . . . . . . . K . . G . . K . . . . . . . . V E E . 1
A/Israel/R83/2016 3C.2a1 . . . . R . . K . . . . . K . T . . . . . Q V . E . 1
A/Israel/R147/2016 3C.2a1 . . . . . . V . . . G . . K . . . . . . . . V . E . 1
A/Israel/B5990/2016 3C.2a1 . S . . . . . . . . . . . K . . . . . . . . V . E . 1
A/Israel/R248/2016 3C.2a . . . D . . . . . K K . . . H . . . . Q . . . . . . 2
A/Israel/R255/2016 3C.2a . . . D . . . . . K K . . . H . . . . Q . . . . . . 2
A/Israel/B5290/2016 3C.2a . . . . . . . . . K K . . . . . . . . Q . . . . . . 2
A/Israel/B6014/2016 3C.2a . . . . . . . . . K E . . . . . . . . Q . . . . . . 2
A/Israel/R256/2016 3C.2a . . Q . . . . K . . . K . . . . . F Y . . . . . . . 3
A/Israel/R250/2016 3C.2a . . Q . . T . K . . . K . . . . . . . . . . . . . . 3
A/Israel/R246/2016 3C.2a R . Q . . . . K . . . K . . . . . . . . . . . . . . 3
A/Israel/R258/2016 3C.2a . . Q . . . . K . . . K . . . . . . . . . . . . . . 3
A/Israel/R127/2016 3C.2a . . . . . . . K . . . K . . . . Y . . . . . . . . . 3
A/Israel/R199/2016 3C.2a . . . . . . . K . . . K . . . . Y . . . . . . . . . 3
A/Israel/R245/2016 3C.2a . . . . . . . K . . . K . . . . Y . . . . . . . . . 3
A/Israel/R274/2016 3C.2a . . . . . . . K . . . K K . . . . . . . . . . . . . 3
A/Israel/B5382/2016 3C.2a . . . . . . . K D . . K . . . . . . . . N . . . . . 3
A/Israel/B6105/2016 3C.2a . . . . . . . K D . . K . . . . . . . . N . . . . I 3
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The other two inﬂuenza viruses that were analyzed by HAI were re-
cognized by an antiserum raised against a cell culture-propagated cul-
tivar of the currently recommended vaccine virus A/Hong Kong/4801/
2014 at titers 4-fold lower and 8-fold lower than the titer of the anti-
serum for the homologous virus. An antiserum raised against the egg-
propagated vaccine virus A/Hong Kong/4801/2014 also recognized the
two viruses analyzed so far at titers 4-fold or greater lower than the titer
of the antiserum for the homologous virus. These results are available in
the report of the Vaccine Composition Meeting held in February [13].
Fig. 2. Phylogenetic analysis of hemagglutinin gene sequences of inﬂuenza A(H3N2) viruses that circulated in Israel in the beginning of the 2016–2017 season.
Analysis was performed with respect to A(H3N2) inﬂuenza viruses that circulated in Israel in previous seasons and reference A(H3N2) inﬂuenza viruses. These virus sequences were
obtained from Global Initiative on Sharing All Inﬂuenza Data (GISAID) (Table 1). Colored branches represent diﬀerent groups of amino acid substitutions, matching the colors of AA
substitution groups in Fig. 1. The 3 groups are indicated.
Fig. 1. Models of structures of representative inﬂuenza A(H3N2) viruses that circulated in Israel in the beginning of the 2016–2017 season.
Each structure represents one amino acid combination that circulated in Israel in the beginning of the 2016–2017 inﬂuenza season. The arrow labels are colored according to the diﬀerent
groups of aa substitutions, similar to the group colors in Table 2. The 3 groups are indicated.
A. Glatman-Freedman et al. Journal of Clinical Virology 93 (2017) 71–75
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4. Discussion
Surveillance of inﬂuenza viruses at the beginning of the inﬂuenza
season is of paramount importance for evaluation of current infecting
viruses and preparation of the appropriate next season vaccine. Israel is
located in the northern hemisphere in western Asia. Inﬂuenza A(H3N2)
predominated in Israel during the preceding seasons of 2010/2011,
2011/2012, 2013/2014 and 2014/2015, in which it constituted 59.5%,
84.3%, 76.4% and 92.2% of the inﬂuenza-positive nasal-throat samples
obtained from ILI sentinel patients, respectively [14–17]. During that
period, the inﬂuenza A(H3N2) vaccine component was modiﬁed sev-
eral times [18]. Amino acid substitutions in the HA protein are con-
sidered to occur more frequently in inﬂuenza A(H3N2) than in inﬂu-
enza A(H1N1) [3,19,20], and a signiﬁcant drift was detected during the
2014–2015 season in the northern hemisphere, dominated by the 3C.2a
clade [7,21]. Based on available vaccination data, 20% of ILI sentinel
patients and at least 36% of hospitalized inﬂuenza A(H3N2)-positive
cases became ill in the beginning of the 2016-2017 season despite being
vaccinated.
In this regard, during the 2014–2015 inﬂuenza season that was
dominated by a drifted inﬂuenza A(H3N2), approximately 20% of in-
ﬂuenza A(H3N2)-positive inﬂuenza received the inﬂuenza vaccine [7].
Nucleotide sequencing revealed several diﬀerences as compared to
the 2016-2017 inﬂuenza A(H3N2) vaccine strain. These changes de-
monstrated genetic divergence into three groups of AA substitution
combinations. One of these combinations (Group 1) belonged to the
newly described clade 3C.2a1 [11] and another (Group 3) was related
to the recently proposed clade 3C.2a2. The remaining combination
(Group 2) was most recently identiﬁed also in Europe [13].
It is interesting to note that inﬂuenza A(H3N2) was detected only in
1.7% of positive inﬂuenza samples received from outpatient sentinel
patients with ILI during the 2015–2016 inﬂuenza season in Israel [22].
Thus, lack of a previous year exposure coupled with the mutations
observed in the circulating viruses may contribute to the spread and
dominance of inﬂuenza A(H3N2) during the present season.
Mutations that cause antigenic drift occur most frequently in the
gene encoding the HA surface glycoprotein, which constitutes the target
of neutralizing antibodies [23]. Inﬂuenza A(H3N2) has ﬁve neutralizing
antigenic sites designated by the letters A to E, with 131 amino acid
positions within them associated with antigenic changes [23]. How-
ever, seven of these positions (145, 155, 156, 158, 159, 189 and 193),
found in antigenic sites A and B, have been more likely to be associated
with antigenic changes [23,24]. None of the AA substitutions detected
in our study occurred in these seven positions. However, the HAI results
may provide some evidence for a possible antigenic drift. It is inter-
esting to note that recent mid-season inﬂuenza A(H3N2) vaccine ef-
fectiveness studies estimates ranged mostly between 38% and 43%
[25–29], which are consistent with modest protection overall.
The detection of three clear and diﬀerent groups of AA substitu-
tions, suggests that continued characterization of inﬂuenza A(H3N2) is
necessary to see which group will prevail, prior to the decision re-
garding the future inﬂuenza vaccine composition.
In summary, characterization of early-season inﬂuenza viruses is
important prior to the decision regarding future inﬂuenza vaccine
composition. Due to the more rapid molecular changes that occur in
inﬂuenza A(H3N2), detecting these changes is of paramount im-
portance.
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